CA3119358A1 - Methods of preparing cytotoxic benzodiazepine derivatives - Google Patents
Methods of preparing cytotoxic benzodiazepine derivatives Download PDFInfo
- Publication number
- CA3119358A1 CA3119358A1 CA3119358A CA3119358A CA3119358A1 CA 3119358 A1 CA3119358 A1 CA 3119358A1 CA 3119358 A CA3119358 A CA 3119358A CA 3119358 A CA3119358 A CA 3119358A CA 3119358 A1 CA3119358 A1 CA 3119358A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- ome
- reacting
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/20—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758814P | 2018-11-12 | 2018-11-12 | |
| US62/758,814 | 2018-11-12 | ||
| PCT/US2019/060677 WO2020102051A1 (en) | 2018-11-12 | 2019-11-11 | Methods of preparing cytotoxic benzodiazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3119358A1 true CA3119358A1 (en) | 2020-05-22 |
Family
ID=68835289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3119358A Pending CA3119358A1 (en) | 2018-11-12 | 2019-11-11 | Methods of preparing cytotoxic benzodiazepine derivatives |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10851117B2 (enExample) |
| EP (2) | EP4361128A3 (enExample) |
| JP (2) | JP7437395B2 (enExample) |
| KR (1) | KR20210098470A (enExample) |
| CN (2) | CN118324848A (enExample) |
| AU (1) | AU2019379104A1 (enExample) |
| CA (1) | CA3119358A1 (enExample) |
| IL (1) | IL283045A (enExample) |
| MA (1) | MA54228A (enExample) |
| SG (1) | SG11202104360YA (enExample) |
| TW (1) | TW202033530A (enExample) |
| WO (1) | WO2020102051A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115448926A (zh) * | 2017-04-20 | 2022-12-09 | 伊缪诺金公司 | 制备吲哚啉并苯并二氮杂䓬衍生物的方法 |
| CA3119358A1 (en) | 2018-11-12 | 2020-05-22 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902707A (en) * | 1985-04-30 | 1990-02-20 | Eli Lilly And Company | Bicyclic pyrazolidinones, compositions and use |
| US5015738A (en) * | 1989-08-07 | 1991-05-14 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo(b)pyrrolobenzodiazepines |
| CN102050824A (zh) * | 2009-11-04 | 2011-05-11 | 上海阳帆医药科技有限公司 | 哌嗪并三唑衍生物 |
| KR20140010076A (ko) | 2011-02-15 | 2014-01-23 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| RU2539658C1 (ru) | 2013-12-10 | 2015-01-20 | Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" | Способ получения бензилхлорида |
| SMT202100092T1 (it) * | 2015-06-29 | 2021-03-15 | Immunogen Inc | Anticorpi anti-cd123 e loro coniugati e derivati |
| MD3313845T2 (ro) * | 2015-06-29 | 2021-02-28 | Immunogen Inc | Conjugați cu anticorpi având cisteină modificată prin inginerie genetică |
| SMT202000004T1 (it) * | 2015-07-21 | 2020-03-13 | Immunogen Inc | Metodi di preparazione dei derivati citotossici di benzodiazepina |
| US20170189548A1 (en) * | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| PL3573948T3 (pl) | 2017-01-25 | 2023-01-30 | Immunogen, Inc. | Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny |
| EP3732178A1 (en) * | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
| CA3119358A1 (en) | 2018-11-12 | 2020-05-22 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
-
2019
- 2019-11-11 CA CA3119358A patent/CA3119358A1/en active Pending
- 2019-11-11 MA MA054228A patent/MA54228A/fr unknown
- 2019-11-11 EP EP24163044.1A patent/EP4361128A3/en not_active Withdrawn
- 2019-11-11 TW TW108140769A patent/TW202033530A/zh unknown
- 2019-11-11 JP JP2021524303A patent/JP7437395B2/ja active Active
- 2019-11-11 CN CN202410421643.7A patent/CN118324848A/zh active Pending
- 2019-11-11 CN CN201980074241.1A patent/CN112996792B/zh not_active Expired - Fee Related
- 2019-11-11 KR KR1020217017972A patent/KR20210098470A/ko not_active Withdrawn
- 2019-11-11 EP EP19817455.9A patent/EP3880681B1/en active Active
- 2019-11-11 WO PCT/US2019/060677 patent/WO2020102051A1/en not_active Ceased
- 2019-11-11 AU AU2019379104A patent/AU2019379104A1/en not_active Abandoned
- 2019-11-11 SG SG11202104360YA patent/SG11202104360YA/en unknown
- 2019-11-11 US US16/679,563 patent/US10851117B2/en active Active
-
2020
- 2020-10-01 US US17/060,611 patent/US11396519B2/en active Active
-
2021
- 2021-05-09 IL IL283045A patent/IL283045A/en unknown
-
2022
- 2022-06-15 US US17/841,046 patent/US11981688B2/en active Active
-
2024
- 2024-02-09 JP JP2024018294A patent/JP2024056819A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3880681B1 (en) | 2024-03-13 |
| EP4361128A3 (en) | 2024-07-17 |
| IL283045A (en) | 2021-06-30 |
| US20210122768A1 (en) | 2021-04-29 |
| JP2024056819A (ja) | 2024-04-23 |
| KR20210098470A (ko) | 2021-08-10 |
| CN118324848A (zh) | 2024-07-12 |
| US11396519B2 (en) | 2022-07-26 |
| TW202033530A (zh) | 2020-09-16 |
| US10851117B2 (en) | 2020-12-01 |
| US11981688B2 (en) | 2024-05-14 |
| SG11202104360YA (en) | 2021-05-28 |
| EP3880681A1 (en) | 2021-09-22 |
| JP7437395B2 (ja) | 2024-02-22 |
| MA54228A (fr) | 2021-09-22 |
| EP4361128A2 (en) | 2024-05-01 |
| CN112996792A (zh) | 2021-06-18 |
| US20230045079A1 (en) | 2023-02-09 |
| CN112996792B (zh) | 2024-04-26 |
| US20200172555A1 (en) | 2020-06-04 |
| JP2022512935A (ja) | 2022-02-07 |
| WO2020102051A1 (en) | 2020-05-22 |
| WO2020102051A8 (en) | 2020-06-18 |
| AU2019379104A1 (en) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024056819A (ja) | 細胞傷害性ベンゾジアゼピン誘導体の調製方法 | |
| US10392407B2 (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| CA2966800C (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| AU2013272701A1 (en) | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | |
| CN105111201B (zh) | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 | |
| JP2020090506A (ja) | 抗体−リファマイシン複合体の製造プロセス | |
| CN110225904B (zh) | 制备细胞毒性苯二氮䓬衍生物的方法 | |
| CA3226162A1 (en) | Aryl compounds and pharmaceutical compositions that modulate ikzf2 | |
| TW202311255A (zh) | 製造血紅素調節劑之方法 | |
| RU2813137C2 (ru) | Способы получения цитотоксических производных бензодиазепина | |
| EP1299388B1 (en) | Variolin derivatives as anti-cancer agents | |
| CA3117113A1 (en) | 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof | |
| EP4592286A1 (en) | Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor | |
| CN103965198A (zh) | 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法 | |
| NZ747420A (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231108 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241126 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250902 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |